Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Aminopyridine SCHEMBL28404259 | 0.83 | GPR119 (0.53) | GPR119POLBMAPK1GRM5CKS1B | |
| 2-Picolinic Acid SCHEMBL28101337 | 0.82 | GPR119 (0.52) | GPR119POLBMAPK1GRM5CKS1B | |
| SCHEMBL28863731 | 0.81 | GPR119 (0.51) | GPR119POLBMAPK1GRM5CKS1B | |
| SCHEMBL28241913 | 0.79 | MAPK1 (0.50) | GPR119POLBMAPK1GRM5CKS1B | |
| SCHEMBL15051069 | 0.78 | GPR119 (0.53) | GPR119POLBMAPK1GRM5CKS1B | |
| Pyridine SCHEMBL28276860 | 0.78 | MAPK1 (0.49) | GPR119POLBMAPK1GRM5 | |
| Benzene SCHEMBL29155321 | 0.77 | USP2 (0.53) | GPR119POLBMAPK1CKS1BSKP1 | |
| Methyl Alcohol SCHEMBL28769289 | 0.77 | USP2 (0.56) | GPR119MAPK1 | |
| SCHEMBL20015325 | 0.76 | GPR119 (0.60) | GPR119POLBGRM5USP30 | |
| Formic Acid SCHEMBL28710276 | 0.76 | USP2 (0.51) | GPR119MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503761-A1 | SUBSTITUTED PIPERAZINES AS MELANOCORTIN RECEPTOR LIGANDS | Neurocrine Biosciences, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20040053933-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2003094918-A1 | SUBSTITUTED PIPERAZINE AS MELANOCORTIN RECEPTORS LIGANDS | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053933-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | MC3R, MC1R, MC5R | GPR119 75/4885POLB 4354/4885MAPK1 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.